Lenz Therapeutics, Inc. balance sheet LENZ

Annual Quarterly

As of Sep 30, 2026, Lenz Therapeutics, Inc. had total assets of $209.7 million and total liabilities of $17.8 million. Total assets were down 0.5% from a year earlier. Stockholders' equity was $192.0 million. It held $30.6 million in cash and investments against $460,000 of total debt, net cash of $30.1 million. The current ratio, current assets divided by current liabilities, was 11.66.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Assets
Cash
31
+20.3%
24
-35.6%
25
+7.5%
25
+24.9%
25
-38.1%
38
-55.2%
23
-88.5%
20
-42.6%
Cash and investments
31
+20.3%
24
-35.6%
25
+7.5%
25
+24.9%
25
-88.3%
38
-80.8%
23
-89.2%
20
-69.4%
Receivables
1
0
0
0
—
—
—
—
Inventory
5
+401.6%
4
3
3
1
—
—
—
Total current assets
207
-0.0%
233
+9.2%
268
+35.6%
301
+42.2%
207
-6.2%
214
+7.1%
198
-8.7%
212
+215.1%
Property and equipment, net
1
-49.1%
1
-14.3%
1
+18.4%
1
+82.6%
1
+238.2%
1
+612.8%
1
+1789.8%
1
+1105.6%
Total assets
210
-0.5%
237
+8.9%
273
+35.4%
306
+42.1%
211
-5.9%
217
+7.3%
201
-7.4%
215
+205.9%
Liabilities and equity
Accounts payable
6
+27.6%
7
+132.9%
11
+198.5%
4
-2.1%
4
+56.5%
3
-35.2%
4
-48.7%
4
-25.5%
Total current liabilities
18
+8.8%
17
+65.5%
26
+201.2%
21
+103.6%
16
+111.6%
10
+21.1%
9
-54.6%
10
-43.8%
Total liabilities
18
+5.8%
17
+58.1%
26
+181.8%
22
+92.0%
17
+92.2%
11
+12.9%
9
-51.8%
11
-43.0%
Stockholders' equity
192
-1.0%
219
+6.2%
246
+28.4%
284
+39.3%
194
-9.9%
206
+7.0%
192
-3.1%
204
+320.1%
Debt
Lease liabilities
0
-51.8%
1
-45.9%
1
-43.1%
1
-37.7%
1
-33.4%
1
-29.0%
1
+299.3%
1
+261.3%
Total debt
0
-51.8%
1
-45.9%
1
-43.1%
1
-37.7%
1
-33.4%
1
-29.0%
1
+299.3%
1
+261.3%
Net cash
30
+23.1%
24
-35.3%
24
+10.2%
24
+29.3%
24
-88.7%
37
-81.2%
22
-89.7%
19
-71.2%
Ratios
Current ratio
11.66x
13.55x
10.40x
14.23x
12.69x
20.54x
23.09x
20.36x
Debt to equity
0.00x
0.00x
0.00x
0.00x
0.00x
0.01x
0.01x
0.01x
Return on equity
-73.06%
-57.47%
-44.22%
-28.88%
-30.36%
-25.39%
-24.86%
-24.39%
Return on assets
-66.88%
-53.26%
-39.99%
-26.85%
-27.95%
-24.11%
-23.72%
-23.12%
Book value per share
6.11
6.98
7.86
9.07
6.78
7.24
6.97
7.42
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
LENZ (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Solana Beach, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1815776
Former names
Graphite Bio, Inc. (until Mar 19, 2024)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.